These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23846936)

  • 21. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
    Bergmann L; Maute L; Heil G; Rüssel J; Weidmann E; Köberle D; Fuxius S; Weigang-Köhler K; Aulitzky WE; Wörmann B; Hartung G; Moritz B; Edler L; Burkholder I; Scheulen ME; Richly H
    Eur J Cancer; 2015 Jan; 51(1):27-36. PubMed ID: 25459392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
    Saif MW
    JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
    Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
    Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New directions in the management of advanced pancreatic cancer: a review.
    Rocha-Lima CM
    Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Dimou AT; Syrigos KN; Saif MW
    JOP; 2011 Mar; 12(2):114-6. PubMed ID: 21386633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
    Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
    Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    Li J; Saif MW
    JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
    Strimpakos AS; Saif MW
    JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.
    Graeven U; Kremer B; Südhoff T; Killing B; Rojo F; Weber D; Tillner J; Unal C; Schmiegel W
    Br J Cancer; 2006 May; 94(9):1293-9. PubMed ID: 16622465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
    Ramfidis VS; Psyrri A; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):286-8. PubMed ID: 25076321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
    Van Cutsem E; Hidalgo M; Canon JL; Macarulla T; Bazin I; Poddubskaya E; Manojlovic N; Radenkovic D; Verslype C; Raymond E; Cubillo A; Schueler A; Zhao C; Hammel P
    Int J Cancer; 2018 Oct; 143(8):2053-2064. PubMed ID: 29756206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
    Xiong HQ; Rosenberg A; LoBuglio A; Schmidt W; Wolff RA; Deutsch J; Needle M; Abbruzzese JL
    J Clin Oncol; 2004 Jul; 22(13):2610-6. PubMed ID: 15226328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
    Senderowicz AM; Johnson JR; Sridhara R; Zimmerman P; Justice R; Pazdur R
    Oncology (Williston Park); 2007 Dec; 21(14):1696-706; discussion 1706-9, 1712, 1715. PubMed ID: 18247017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
    Mura S; Buchy E; Askin G; Cayre F; Mougin J; Gouazou S; Sobot D; Valetti S; Stella B; Desmaele D; Couvreur P
    Biochimie; 2016 Nov; 130():4-13. PubMed ID: 27519301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
    Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH
    Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
    Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
    Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel agents in early phase clinical studies on refractory pancreatic cancer.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Mar; 13(2):166-8. PubMed ID: 22406592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advancements in the management of pancreatic cancer.
    Li J; Saif MW
    JOP; 2009 Mar; 10(2):109-17. PubMed ID: 19287102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.